MarketMoodz
Deutsche Bank Starts ATAI Coverage With Buy, $12 Target
Deutsche Bank has started coverage on ATAI Life Sciences with a Buy rating and a $12 price target. The note frames ATAI as a potential leader in the growing psychedelic-therapy space, signaling upside if trials and regulatory progress align.
Key Takeaways
- Buy rating and a $12 price target imply >250% upside from the prior close
- ATAI's pipeline includes BPL-003, VLS-01 and EMP-01 for treatment-resistant depression
- DB's model cites peak U.S. sales: BPL-003 up to $4B, VLS-01 up to $2B, EMP-01 up to $1B
- AtaiBeckley collaboration positions ATAI in the forefront of psychedelic medicine
People Involved
- David HoangDeutsche Bank Analyst
Entities Involved
- ATAI Life Sciences (ATAI)Biotech company developing psychedelic therapies
- Deutsche BankInvestment bank initiating coverage
- Beckley PsytechCollaboration partner with ATAI
- Spravato (Janssen/Johnson & Johnson)Benchmark for antidepressant sales
MarketMoodz Analysis
The note from Deutsche Bank underscores ATAI’s potential to convert a nascent psychedelic-therapy pipeline into multi-billion-dollar revenue if key trials succeed and regulatory pathways clear. For investors, the key question is whether ATAI can translate early-stage programs into durable commercial franchises, given the clinical and regulatory risks that still loom.
Historically, the psychedelic space has moved from niche trials to mainstream attention, with Spravato setting an annualized sales benchmark near $2 billion and a potential peak well above that. Deutsche Bank’s call hinges on ambitious peak-sales assumptions for BPL-003, VLS-01, and EMP-01, making sensitivity to trial readouts and regulatory updates a central risk factor.
What to watch next: upcoming trial readouts and any regulatory milestones, updates on the AtaiBeckley collaboration, and broader funding dynamics that could re-rate ATAI on success signals rather than speculation.
Source: Original Article